ALNY Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

305.680

Open

302.430

VWAP

301.76

Vol

2.28M

Mkt Cap

40.32B

Low

297.620

Amount

687.43M

EV/EBITDA(TTM)

50.10

Total Shares

133.51M

EV

40.43B

EV/OCF(TTM)

56.71

P/S(TTM)

9.65

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Show More

Events Timeline

(ET)

2026-05-12

05:50:00

Alnylam Releases New Analyses Supporting Vutrisiran for Cardiac Amyloidosis Treatment

2026-05-07 (ET)

2026-05-07

09:40:00

MBX Biosciences Appoints Mark Soued as Chief Commercial Officer

2026-04-30 (ET)

2026-04-30

08:10:00

Alnylam Reports Q1 Revenue of $1.167B

2026-04-06 (ET)

2026-04-06

07:10:00

BioCryst Appoints Sandeep Menon as Chief R&D Officer

2026-03-30 (ET)

2026-03-30

13:10:00

Alnylam Releases New Cardiovascular Data, Vutrisiran Significantly Improves Patient Quality of Life

News

Newsfilter

05-28Newsfilter

Avaí Bio Achieves Milestone in α-Klotho Cell Bank Development

seekingalpha

05-19seekingalpha

Citi Initiates Bullish Coverage on SMid Cap Biotechs

NASDAQ.COM

05-19NASDAQ.COM

Analysis of IBB ETF Trading Dynamics

Newsfilter

05-12Newsfilter

Alnylam's New Therapy Reduces Cardiovascular Event Risks

Newsfilter

05-04Newsfilter

Alnylam to Present New Vutrisiran Data at Heart Failure 2026

Yahoo Finance

05-03Yahoo Finance

Alnylam Pharmaceuticals Q1 Results Exceed Expectations

17 Analyst Rating

Wall Street analysts forecast ALNY stock price to rise

14 Buy

3 Hold

0 Sell

Strong Buy

Current: 0.000

Low

351.00

Averages

479.53

High

580.00

Current: 0.000

Low

351.00

Averages

479.53

High

580.00

Citi

NULL

to

Buy

initiated

$380

AI Analysis

2026-05-18

Reason

Citi

Price Target

$380

AI Analysis

2026-05-18

initiated

NULL

to

Buy

Reason

Citi initiated coverage of Alnylam with a Buy rating and $380 price target. The expanded launch of Amvuttra for ATTR-CM has \"no doubt been impressive,\" says the analyst, who views 28% year-to-date pullback as \"an attractive long-term entry point.\" Pressure has been led by competitor concerns, but the firm sees \"more tailwinds than headwinds for Amvuttra,\" the analyst added.

Morgan Stanley

Equal Weight

maintain

$360 -> $370

2026-05-01

Reason

Morgan Stanley

Price Target

$360 -> $370

2026-05-01

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Alnylam to $370 from $360 and keeps an Equal Weight rating on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ALNY

Unlock Now

Valuation Metrics

The current forward P/E ratio for Alnylam Pharmaceuticals Inc (ALNY.O) is 31.65, compared to its 5-year average forward P/E of -38.12. For a more detailed relative valuation and DCF analysis to assess Alnylam Pharmaceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-38.12

Current PE

31.65

Overvalued PE

36.81

Undervalued PE

-113.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-7408.37

Current EV/EBITDA

22.53

Overvalued EV/EBITDA

51057.40

Undervalued EV/EBITDA

-65874.14

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

14.21

Current PS

5.42

Overvalued PS

18.64

Undervalued PS

9.79

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

resistant to inflation stocks

Intellectia · 41 candidates

Sector: Consumer Cyclicals, Consumer Non-Cyclicals, Healthcare, Healthcare Services & Equipment, Industrials, Industrial & Commercial Services, Industrial Goods, UtilitiesIndustry: Electronic Equipment & Parts, Electric Utilities & IPPs, Food & Drug Retailing, Food & Tobacco, Healthcare Equipment & Supplies, Healthcare Providers & Services, Multiline Utilities, Pharmaceuticals, Professional & Commercial Services, Professional & Business Education, Water & Related UtilitiesRegion: USGross Margin: >= 40.00Beta: LowRiskCurrent Ratio: >= 1.50Operating Margin: >= 10.00Free Cash Flow Ttm: >= 0

Ticker

Name

Market Cap$

Halozyme Therapeutics Inc

8.14B

Zevra Therapeutics Inc

647.31M

Alnylam Pharmaceuticals Inc

39.47B

Innoviva Inc

1.63B

Gilead Sciences, Inc

165.99B

Cintas Corp

67.97B

What stocks have a new buy signal today?

Intellectia · 55 candidates

Market Cap: >= 5.00BRegion: USMarket Cap Category: large, mega, midPrice Change Pct: >= $4.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceCrossAboveMA20, PriceAboveMA200

Ticker

Name

Market Cap$

Arm Holdings PLC

143.33B

Summit Therapeutics Inc

12.05B

Chewy Inc

9.73B

Planet Labs PBC

11.02B

AST SpaceMobile Inc

33.23B

Rocket Lab Corp

37.62B

Intellectia · 50 candidates

Market Cap: >= 5.00BRegion: USAnalyst Consensus: Strong BuyAnalyst Action: UpgradeList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePrice

Ticker

Name

Market Cap$

Terawulf Inc

6.22B

Kinross Gold Corp

36.68B

Advanced Micro Devices Inc

315.31B

Broadcom Inc

1.53T

Applovin Corp

154.70B

MongoDB Inc

20.94B

strong buy best stock to trade next week ?

Intellectia · 84 candidates

Market Cap: >= 10.00BMarket Cap Category: mega, largeAnalyst Consensus: Strong BuyList Exchange: XNYS, XNASOne Week Rise Prob: >= 70Monthly Average Dollar Volume: >= 3,000,000

Ticker

Name

Market Cap$

Ecolab Inc

86.95B

Ascendis Pharma A/S

14.47B

Webster Financial Corp

11.63B

Nu Holdings Ltd

72.74B

MP Materials Corp

10.46B

Taiwan Semiconductor Manufacturing Co Ltd

1.94T

stock to increase price today and tomorrow

Intellectia · 116 candidates

Price Change Pct: >= $0.01Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 65One Day Predict Return: >= 1.0%

Ticker

Name

Market Cap$

PEDEVCO Corp

59.31M

First BanCorp

3.52B

Jerash Holdings (US) Inc

41.91M

Ryman Hospitality Properties Inc

6.43B

Kestrel Group Ltd

92.75M

Sify Technologies Ltd

1.08B

Show me stocks with strong buy sentiment

Intellectia · 45 candidates

Market Cap: >= 10.00BAnalyst Consensus: Strong BuyQuarter Eps Yoy Growth: >= 10.0%List Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceMonthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

NVIDIA Corp

4.58T

Microsoft Corp

3.07T

Broadcom Inc

1.61T

Advanced Micro Devices Inc

348.21B

SAP SE

247.14B

Applovin Corp

159.83B

Day projection December 5 2025

Intellectia · 65 candidates

Market Cap: >= 10.00BAnalyst Consensus: Strong BuyTarget Price Upside Potential: MoreAbovePrice

Ticker

Name

Market Cap$

NVIDIA Corp

4.45T

Microsoft Corp

3.30T

Broadcom Inc

1.56T

Meta Platforms Inc

1.54T

SAP SE

262.15B

Applovin Corp

179.98B

find me very strong buy stocks

Intellectia · 18 candidates

Market Cap: >= 30.00BAnalyst Consensus: Strong BuyWeekly Average Turnover: >= 1,000,000Target Price Upside Potential: MoreAbovePriceEarnings Surprise: BothBeat

Ticker

Name

Market Cap$

NVIDIA Corp

4.45T

Broadcom Inc

1.56T

Applovin Corp

179.98B

Uber Technologies Inc

175.08B

Arista Networks Inc

160.29B

Intuit Inc

146.07B

what are stock with zacks buy rank 1 ?

Intellectia · 45 candidates

Analyst Consensus: Strong BuyEps Ttm: >= 0Revenue 5yr Cagr: >= 10Return On Equity: >= 15.0%Target Price Upside Potential: MoreAbovePrice

Ticker

Name

Market Cap$

NVIDIA Corp

4.45T

Microsoft Corp

3.30T

Broadcom Inc

1.56T

Meta Platforms Inc

1.54T

Uber Technologies Inc

175.08B

Arista Networks Inc

160.29B

stocks that have earnings

Intellectia · 19 candidates

Market Cap: >= 20.00BAnalyst Consensus: Moderate Buy, Strong BuyWeekly Average Turnover: >= 10,000,000Target Price Upside Potential: MoreAbovePrice

Ticker

Name

Market Cap$

Shopify Inc

180.36B

Arista Networks Inc

160.29B

Constellation Energy Corp

106.67B

BP PLC

92.25B

DoorDash Inc

88.99B

Ferrari NV

79.94B

Whales Holding ALNY

Bluebox Asset Management Uk Ltd.

Two Sigma Investments, LP

Nomura Asset Management Taiwan Ltd.

Jacobs Levy Equity Management Inc

Capital Research

Voleon Capital Management LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Alnylam Pharmaceuticals Inc (ALNY) stock price today?

The current price of ALNY is 301.98 USD — it has decreased -1.01

What is Alnylam Pharmaceuticals Inc (ALNY)'s business?

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

What is the price predicton of ALNY Stock?

Wall Street analysts forecast ALNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALNY is479.53 USD with a low forecast of 351.00 USD and a high forecast of 580.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Alnylam Pharmaceuticals Inc (ALNY)'s revenue for the last quarter?

Alnylam Pharmaceuticals Inc revenue for the last quarter amounts to 1.17B USD, increased 96.43

What is Alnylam Pharmaceuticals Inc (ALNY)'s earnings per share (EPS) for the last quarter?

Alnylam Pharmaceuticals Inc. EPS for the last quarter amounts to 1.51 USD, decreased -1178.57

How many employees does Alnylam Pharmaceuticals Inc (ALNY). have?

Alnylam Pharmaceuticals Inc (ALNY) has 2500 emplpoyees as of May 31 2026.

What is Alnylam Pharmaceuticals Inc (ALNY) market cap?

Today ALNY has the market capitalization of 40.32B USD.